Core Insights - Shouyao Holdings (688197) has filed an international patent application for a method of preparing an enzyme inhibitor, with the application number PCT/CN2025/110439 and an international publication date set for January 29, 2026 [1] - The company has announced a total of three international patent applications in 2023 [1] - In the first half of 2025, Shouyao Holdings invested 108 million yuan in research and development, reflecting a year-on-year increase of 1% [1]

Group 1 - The company expects a significant decline in revenue for the year 2025, projecting an operating income between 120 million to 150 million yuan, a decrease of 113.28 million to 143.28 million yuan compared to the previous year, representing a year-on-year decline of 43.03% to 54.42% [3] - The company anticipates a net loss attributable to shareholders of the parent company ranging from -160 million to -120 million yuan, which is a reduction in loss of 196.90 million to 236.90 million yuan compared to the previous year, indicating a year-on-year decrease in loss of 55.17% to 66.38% [3] - The projected net loss attributable to shareholders after excluding non-recurring gains and losses is expected to be between -165 million to -125 million yuan, with a reduction in loss of 193.53 million to 233.53 million yuan compared to the previous year, reflecting a year-on-year decrease in loss of 53.98% to 65.14% [4] Group 2 - The company reported a total profit loss of -388.64 million yuan for the year 2024, with a net loss attributable to shareholders of the parent company at -356.90 million yuan [6] - The earnings per share for the year 2024 were reported at -1.3007 yuan [7] Group 3 - The decline in performance is attributed to intensified market competition due to domestic pharmaceutical industry procurement policies and the introduction of similar competing products, along with a decrease in flu cases in the first three quarters of 2025, leading to reduced operating income and gross margin [8] - The company has maintained a high level of R&D investment to sustain its core competitiveness while implementing cost control measures, resulting in a significant decrease in sales and management expenses compared to the previous year [8] - Future strategies include adjusting marketing strategies, accelerating R&D progress, launching new products, optimizing product sales structure, and enhancing cost management to achieve sustainable and high-quality development [8]

Core Viewpoint - The report presented at the AASLD annual meeting is a significant showcase of the company's progress in innovative drug development for hepatitis B treatment, aimed at gaining international attention in the field of hepatology and fostering friendly international exchanges and discussions [1] Group 1 - The company is committed to steadily advancing the clinical research and development of innovative hepatitis B drugs [1] - The company will fulfill its obligation to disclose information regarding the progress of innovative drugs in a timely manner, in accordance with regulations [1]

针对本期业绩变化的主要原因，博瑞医药表示主要受流感趋势变化、竞争格局变化、客户阶段性商业需 求波动等影响，使得当期营业收入及产品毛利额减少，以及在建工程陆续完工转固带来计提折旧增加， 同时创新药等研发投入加大使得研发费用等期间费用同比有所增加。 北京商报讯（记者 丁宁）1月30日晚间，博瑞医药（688166）发布2025年业绩预告显示，经财务部门初 步测算，预计2025年实现归属净利润4130万元到6190万元，与上年同期相比将同比减少67.28%到 78.17%。 ...

Company Overview - The company specializes in the development of new drugs, including HC-1119, HP518, HP568, HP501, HP515, HP537, and HP560 [8] - The first class new drug, HC-1119, is expected to be approved for sale in May 2025, leading to a modest increase in sales revenue from material and intermediate sales [8] Financial Performance - The company anticipates total revenue for 2025 to be between 19 million and 22 million yuan, influenced by the inclusion of HC-1119 in the National Medical Insurance Drug List, which will result in a significant price reduction [8] - Research and development expenses for 2025 are projected to be between 105 million and 125 million yuan, a decrease of 4.903 million to 6.903 million yuan compared to the previous year [8] - The company expects to report a net loss for 2025, although the loss will be reduced compared to the previous year when excluding non-recurring gains and losses [9] Historical Revenue and Profit Trends - Historical total revenue and net profit data indicate fluctuations, with total revenue expected to show a growth rate of -1,000% to 6,000% from 2020 to 2025 [10] - The company has experienced varying growth rates in total revenue and net profit over the years, with specific projections for 2025 indicating a continued trend of net losses [10] Valuation Metrics - The company’s valuation metrics include price-to-earnings (P/E) ratio, price-to-book (P/B) ratio, and price-to-sales (P/S) ratio, with P/E being negative during loss periods, making P/B and P/S more relevant for valuation [13]

Core Viewpoint - The company Haipru (002399) has disclosed its earnings forecast for 2025, expecting a significant decline in net profit attributable to shareholders, while projecting an increase in non-recurring net profit [2] Financial Performance - The forecasted net profit for 2025 is estimated to be between 284 million yuan and 377 million yuan, representing a year-on-year decrease of 41.71% to 56.09% [2] - The projected non-recurring net profit is expected to be between 362 million yuan and 460 million yuan, indicating a year-on-year growth of 42.78% to 81.43% [2] - Basic earnings per share are estimated to be between 0.1936 yuan and 0.2569 yuan [2] Valuation Metrics - As of January 30, the company's price-to-earnings ratio (TTM) is approximately between 48.14 and 63.91 times, with a price-to-book ratio (LF) of about 1.47 times and a price-to-sales ratio (TTM) of around 3.36 times [2] Business Overview - The company primarily operates in the heparin industry chain, biopharmaceutical CDMO, and the investment, development, and commercialization of innovative drugs, aiming to provide high-quality and effective medications and services globally [10] - The company has achieved significant results in expanding its heparin product market, with steady sales growth across various regions and a continuous increase in market share [10] Profitability Trends - The decline in net profit attributable to shareholders is mainly due to a high base from the previous year, which included over 350 million yuan in one-time investment income [10] - The company's joint ventures are expected to impact net profit due to unmet research and development progress, with the final impact to be confirmed by the accounting firm [10]

海南海药公告，预计2025年度净利润为负值。报告期内，公司归属于上市公司股东的净利润预计为亏损 3.5亿元至4.3亿元，亏损额较上年同期有所下降。 ...

Core Viewpoint - Newnow (300765) announced a change in its management, appointing Dai Long as the new General Manager while he also holds the positions of Board Secretary and Securities Affairs Representative [1][4] Management Changes - Dai Long, born in June 1992, has a background in finance and has been with Newnow since December 2016, serving in various roles including Financial Manager and Board Secretary [4] - Despite being appointed to a key position, Dai Long does not hold any shares in Newnow and has no connections with major shareholders or other executives [4] - Dai Long's total pre-tax compensation for 2024 is reported at 223,200 yuan, a decrease of 121,100 yuan from 2023 [4][6] Executive Compensation - Other executives at Newnow also experienced significant salary reductions in 2024, with Vice General Manager Liu Gang's compensation dropping to 188,800 yuan, a decline of 18.89% year-on-year [7] - The collective salary cuts among executives are linked to the company's poor performance [7] Financial Performance - In 2024, Newnow reported revenues of 1.981 billion yuan, a year-on-year decrease of 21.98%, and a net profit attributable to shareholders of 53.7263 million yuan, down 87.63% [7] - The company anticipates further losses in 2025, projecting a net profit attributable to shareholders between -255 million yuan and -170 million yuan [7] Business Overview - Newnow, a core subsidiary of CSPC Pharmaceutical Group, was established in 1989 and went public in 2019 [7] - It is the largest production base for chemical synthetic xanthine products globally, with key products including caffeine and theobromine [7] - The company has developed a dual-driven business model focusing on traditional functional foods and innovative biopharmaceuticals [8] Strategic Developments - Newnow's subsidiary, Jushi Biotech, signed a strategic cooperation agreement with AstraZeneca for eight innovative long-acting peptide drug projects, with AstraZeneca agreeing to pay a $1.2 billion upfront fee and up to $17.3 billion in milestone payments [8] - Newnow plans to list on the Hong Kong Stock Exchange to expand financing channels for innovative drug research and development [8] - The company increased its stake in Jushi Biotech to 80% by acquiring 29% of its shares for 1.1 billion yuan [8] Market Performance - As of January 30, Newnow's stock price closed at 38.87 yuan per share, reflecting a decline of 15.72%, with a total market capitalization of 54.6 billion yuan [9]

Core Viewpoint - The company is proactively addressing potential fluctuations in the vitamin A market prices for 2025 by optimizing its business model and strengthening internal management [1] Group 1 - The company responded to investor inquiries on an interactive platform regarding its strategies for the vitamin A market [1] - The company emphasizes that specific operational data should be referenced from official announcements [1]

（编辑 任世碧） 证券日报网讯 1月30日，博瑞医药发布2025年年度业绩预告称，公司预计2025年年度归属于母公司所有 者的净利润4，130万元到6，190万元，与上年同期（法定披露数据）相比将同比减少67.28%到 78.17%。 ...